Teva isotretinoin 30 mg capsules recalled as superpotent and subpotent
Teva is recalling three lots of Isotretinoin Capsules, USP, 30 mg because the product was found to be superpotent and subpotent. 21,984 packages are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for out-of-specification potency in both directions, which can under- or over-dose the patient, a risk of harm with no injuries reported.
Plain-English summary
Teva Pharmaceuticals USA, Inc is recalling Isotretinoin Capsules, USP, 30 mg, supplied in 10 count prescription packs, carton NDC 0591-2435-15 and blister pack NDC 0591-2435-45. The action covers 21,984 packages.
The stated reason is that the product was found to be superpotent and subpotent, meaning capsules fell outside the approved specification for the amount of active ingredient. The FDA classified the action as Class II.
Affected lots are 100055426 (exp 02/2026), 100071518 (exp 04/2027) and 100072450 (exp 07/2027). Distribution was to Florida, Ohio, Puerto Rico and Mississippi.
This is a prescription medicine. Patients should not stop taking a prescribed course without medical advice; anyone holding an affected lot should contact their pharmacy or prescriber about a replacement supply.
The recalled product
- Product
- ISOTRETINOIN (ISOTRETINOIN)
- Brand
- ISOTRETINOIN
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Category
- Drug — Oral capsule
- Affected units
- 21,984
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lots 100055426
- Exp. date 02/2026
- 100071518
- Exp. date 04/2027 & 100072450
- Exp. Date 07/2027
Distribution
Part of a larger recall action
This product is one of 2 recalled by Teva Pharmaceuticals USA, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · ISOTRETINOIN
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
- HighPrescription Drug Isotretinoin Recalled Due to Over-Potent Formulation
FDA (Drugs) · 2024-04-17
- LowAmneal Recalls Isotretinoin Capsules Due to Tretinoin Impurity Levels
FDA (Drugs) · 2019-11-20
Same manufacturer · Teva Pharmaceuticals USA, Inc
See all →- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine transdermal patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- ModerateTeva clonidine 0.3 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- ModerateTeva clonidine 0.2 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
Same hazard · superpotent
See all →- HighFDA Recalls Levothyroxine Sodium Tablets for Potency Variation
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Tablets
FDA (Drugs) · 2024-12-18
- HighHand Sanitizer Recalled for Chemical Impurities and Manufacturing Defects
FDA (Drugs) · 2023-01-25
- HighMacleods Pharma Recalls Pioglitazone Tablets Due to Superpotent Content
FDA (Drugs) · 2019-10-23
- SevereVirtus Recalls Hyoscyamine Sulfate Tablets Due to Content Uniformity Failures
FDA (Drugs) · 2016-12-28